Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Phase 2EnobosarmSemaglutidePositive

AI Analysis

Summary

Veru announced full enrollment of its Phase 2b PLATEAU clinical trial evaluating the combination of Enobosarm and Semaglutide for high quality weight loss, achieving and exceeding the targeted enrollment of 200 patients.

Clinical Trial Data

Phase

Patients

200

Importance:5/10

Sentiment:

0.60

clinical trialenrollmentcombination therapyweight lossPhase 2b

Related Companies

$VERU

Read the original article

Published by GlobeNewswire Clinical Studies on July 27, 2026 12:10 PM

Read Original